July 15, 2026 05:14 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Taslima Nasrin announces Kolkata return after 20 years to attend literary event at Rabindra Sadan | 'We must not watch one of our greatest minds be sacrificed': Zeenat Aman backs Sonam Wangchuk, urges govt to open dialogue | 'I don't want Phunsukh Wangdu to die': '3 Idiots' star Omi Vaidya's emotional appeal for Sonam Wangchuk | Middle East Crisis: Iran strikes UAE tankers in Strait of Hormuz, Indian crew member killed | Picnic turns into horror: Woman allegedly harassed, family chased for 15 km in Nashik | 'Mannat is a private property': Supreme Court clears renovation of Shah Rukh Khan's Bandra residence | Bengal CM Suvendu Adhikari backs move to stop entry to Bankra Mosque inside Kolkata airport operational area | Big win for Vijay government! Supreme Court stays Madras HC's cow slaughter ban in Tamil Nadu | Badrinath Temple donation theft case: Key accused Pramod Nautiyal arrested in major breakthrough | 'Citizenship must be decided fairly': Supreme Court quashes Gauhati HC order declaring 27 as foreigners
Coronavirus Vaccine

Adar Poonawalla thanks PM Modi for decisive 'policy changes and swift financial aid' amid vaccine shortage

| @indiablooms | Apr 21, 2021, at 07:18 am

Mumbai/IBNS: Serum Institute of India (SII) CEO Adar Poonawalla has lauded the Centre's policy change in vaccination, bringing all above 18 under the mass drive and extending financial support to the vaccine manufacturers.

SII which is manufacturing Covishied, developed by Oxford University and Swedish drug giant AstraZeneca, in India has been given Rs 3,000 crore as 100 per cent advance till July, reported NDTV citing senior sources in the Finance Ministry.

A similar advance of Rs 1,500 crore has been given to Hyderabad-based Bharat Biotech, the producer of indegenous Covaxin, the report added.

"This will ensure that the two companies get necessary funding to continue and scale up production," the sources said, the report added.

Earlier, Adar Poonawalla had appealed to the Centre for funds to scale up manufacturing amid high demand of the vaccine within and outside India.

Both Bharat Biotech and SII were facing shortage of funds "to scale up production, purchase raw materials, pay staff, and make and distribute enough doses of the vaccines", stated the report.

Poonawall, on Tuesday, tweeted in appreciation of the Centre's move.

The states can now buy coronavirus vaccine doses directly from manufacturers in the "liberalised and accelerated Phase 3 strategy of COVID-19 vaccination".

.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.